Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

LIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

REVENUES:

Sales $489,664 $428,729 $1,408,603 $1,287,802

Other revenues 8,818 9,692 25,813 34,865

498,482 438,421 1,434,416 1,322,667

COSTS AND EXPENSES:

Cost of sales 121,477 82,258 312,711 251,970

Research and development 88,325 93,527 250,169 274,078

Selling, general and

administrative 222,948 186,456 631,832 527,962

Settlement reserve 7,450 369,000 7,450 425,000

Restructuring charges 1,497 - 6,973 -

In-process research and

development - - 10,000 -

441,697 731,241 1,219,135 1,479,010

INCOME (LOSS) FROM

OPERATIONS 56,785 (292,820) 215,281 (156,343)

OTHER INCOME (EXPENSE):

Interest income 4,002 8,868 15,515 23,485

Interest expense (8,831) (5,660) (25,697) (15,272)

Gain on extinguishment of

debt - 5,319 - 5,319

Gain on sale of investment - - - 5,791

Other income (expense), net (2,284) 2,493 1,488 3,747

(7,113) 11,020 (8,694) 23,070

INCOME (LOSS) BEFORE INCOME

TAXES
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 21, 2014 Shimadzu Scientific Instruments introduces ... tool for the pain management and clinical markets. The ... and review by allowing users to highlight and review ... , QuantAnalytics allows analysts to filter results by group ... processing by eliminating the need to sift through analytes ...
(Date:10/22/2014)... 2014 Grace Century, a private equity ... announces the addition of Dr. Yousef “Josh” Siddiqui ... team. Dr. Siddiqui will provide further healthcare expertise to ... of University College Medical School in the ... in 2001. With further certification as a General Practitioner ...
(Date:10/22/2014)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... its Oral Amphotericin B program.  The company recently ... work involving samples from HIV/AIDS patients exposed ... pre clinical studies and regulatory filings to move ... utilizing approximately $700,000 of funding and technological advice ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market ... Labeling Systems, Table-top Counters) by End-user (Inpatient Pharmacy ... Trends to 2019” analyzes and studies the major ... Europe, Asia-Pacific, and the Rest of the World ... figures spread through 300 pages and in-depth TOC ...
Breaking Biology Technology:Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
... Sciences,Holdings, Inc. (Nasdaq: ADLS ) a biopharmaceutical company ... in the,therapeutic areas of infection, cancer and respiratory diseases, ... Bank to increase,its line of credit from $4 million ... by 12 months to January 1, 2011. The closing ...
... Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) today announced ... Oncolytic Reovirus (REOLYSIN(R)) in Combination with,Carboplatin/Paclitaxel in ... in the November/December issue of the Journal ... Society for Biological Therapy of,Cancer (iSBTc). The ...
... 23 Schering-Plough,Corporation (NYSE: SGP ) ... has met the primary endpoint in a ... administered as a,fast-dissolving sublingual tablet, is a ... The study was a randomized, placebo-controlled, ...
Cached Biology Technology:Advanced Life Sciences Completes Debt Transaction 2Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting 2Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting 3Asenapine Meets Primary Endpoint in Long-Term Schizophrenia Relapse Prevention Trial 2
(Date:10/15/2014)... our ability to assess the pandemic risk from strains ... we must not allow ourselves to become complacent that ... international consortium of scientists. , Influenza pandemics arise when ... yet to develop widespread immunity – spreads in the ... the past 100 years, the worst of which – ...
(Date:10/15/2014)... Johannes Gutenberg University Mainz (JGU) as a full ... to maintain a significant nationwide standing in the ... of Johannes Gutenberg University Mainz as a full ... the national and international competition for the best ... can be proud that Mainz University has been ...
(Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... light on the multi-decade debate about how the brain knows where ... watch your legs and feet when you walk. Your brain knows ... how the brain achieves this: , (1) the outflow hypothesis says ... them how strongly to contract, and uses this to predict where ...
... shows there's a constant shuffling of genetic endowments going ... seems to be a flood of viruses, MIT scientists ... W. Chisholm, is uncovering a challenging new facet of ... exploit changing conditions such as altered light, temperature and ...
... the brain enhances long-term storage of fearful memories ... of Medicine researchers report this week in Nature ... demonstrate evidence of enhancements in memory reconsolidation in ... associate professor in the Department of Psychiatry. "Understanding ...
Cached Biology News:How does the brain know what the right hand is doing? 2MIT: Oceans are a major gene swap-meet for plankton 2MIT: Oceans are a major gene swap-meet for plankton 3MIT: Oceans are a major gene swap-meet for plankton 4Activation of a protein solidifies fear memory in the brain 2
...
... glycerol stocks contained in standard 96-well microtiter ... with approximately 5,000 clones per plate. After ... well, the corresponding subplate is screened with ... positive well(s). Cells from a positive well ...
... benchmark for analytical performance ... and the ultimate in analytical,performance, ... Varian 810-MS features include: , ... minimize,interferences, providing reliable, routine, trace ...
... A full-featured high-performance ICP-MS system designed ... sampling interface, Omega II off-axis ion lens, ... the 7500a can handle the widest range ... 2003, the 7500a now includes as standard ...
Biology Products: